Real‐world effectiveness of adjuvant octreotide therapy in patients with pancreatic neuroendocrine tumors at high recurrence risk: A multicenter retrospective cohort study

Adjuvant therapy for pancreatic neuroendocrine tumors (PanNETs) after radical resection lacks evidence‐based data and remains controversial. This study aimed to validate whether long‐acting octreotide is a potential candidate for adjuvant therapy in patients with G2 PanNETs at high recurrence risk b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuroendocrinology 2024-12, Vol.36 (12), p.e13442-n/a
Hauptverfasser:	Guo, Shiwei, Wu, Heshui, Gao, Suizhi, Hu, Weiyu, Jiang, Hui, Bian, Yun, Zhang, Yijie, Li, Bo, Li, Gang, Xu, Xuefeng, Wang, Min, Zhu, Chenglin, Qu, Linlin, Huang, Qiang, Qin, Renyi, Lou, Wenhui, Jin, Gang
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant therapy Adult Aged Antineoplastic Agents, Hormonal - therapeutic use Chemotherapy, Adjuvant Disease-Free Survival Female Humans Lymph nodes Male Metastases Middle Aged Neoplasm Recurrence, Local - drug therapy Neuroendocrine system Neuroendocrine tumors Neuroendocrine Tumors - drug therapy Octreotide Octreotide - administration & dosage Octreotide - therapeutic use Pancreas Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pancreatic Neoplasms - surgery pancreatic neuroendocrine tumors radical resection Retrospective Studies Survival Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!